PMID- 24463347
OWN - NLM
STAT- MEDLINE
DCOM- 20140929
LR  - 20151119
IS  - 1531-703X (Electronic)
IS  - 1040-8746 (Linking)
VI  - 26
IP  - 2
DP  - 2014 Mar
TI  - Recent advances in primary cutaneous B-cell lymphomas.
PG  - 230-6
LID - 10.1097/CCO.0000000000000060 [doi]
AB  - PURPOSE OF REVIEW: In the last decade, there has been considerable debate 
      regarding the classification and terminology of the group of primary cutaneous 
      B-cell lymphomas (CBCLs). With the introduction of the WHO-EORTC classification 
      for cutaneous lymphomas, three main types of CBCLs are recognized: primary 
      cutaneous marginal zone B-cell lymphoma (PCMZL), primary cutaneous follicle 
      centre lymphoma (PCFCL) and primary cutaneous large B-cell lymphoma, leg type 
      (PCLBCL, LT). RECENT FINDINGS: Epidemiological studies performed on different 
      patient cohorts showed that the CBCL entities described in the WHO-EORTC 
      classification and the 4th WHO classification of tumours of haematopoietic and 
      lymphoid tissues are reproducible worldwide and are clinically relevant, thereby 
      illustrating the clinical usefulness of the WHO-EORTC classification. 
      Furthermore, collaborative studies between the ISCL and EORTC lymphoma group 
      resulted in recommended staging procedures and consensus treatment 
      recommendations for different CBCL subtypes. SUMMARY: The advances in the 
      classification, staging procedures and treatment of CBCLs have led to a major 
      improvement in clinical care. The progress in CBCL classification enables 
      molecular studies on well defined groups of patients and facilitates comparison 
      of treatment results between different centres. Recent studies found that 
      intralesional/intravenous rituximab has a therapeutic value in PCFCL and PCMZL 
      with widespread cutaneous lesions and suggest that therapies targeting the 
      nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway 
      could be helpful in DLBCL, LT.
FAU - Vermeer, Maarten H
AU  - Vermeer MH
AD  - Department of Dermatology, Leiden University Medical Center, Leiden, The 
      Netherlands.
FAU - Willemze, Rein
AU  - Willemze R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NF-kappa B)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antibodies, Monoclonal, Murine-Derived/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Humans
MH  - Lymphoma, B-Cell/classification/drug therapy/*pathology
MH  - NF-kappa B/metabolism
MH  - Neoplasm Staging
MH  - Rituximab
MH  - Signal Transduction/drug effects
MH  - Skin Neoplasms/classification/drug therapy/*pathology
EDAT- 2014/01/28 06:00
MHDA- 2014/09/30 06:00
CRDT- 2014/01/28 06:00
PHST- 2014/01/28 06:00 [entrez]
PHST- 2014/01/28 06:00 [pubmed]
PHST- 2014/09/30 06:00 [medline]
AID - 10.1097/CCO.0000000000000060 [doi]
PST - ppublish
SO  - Curr Opin Oncol. 2014 Mar;26(2):230-6. doi: 10.1097/CCO.0000000000000060.